Tables of Rules

INTEGRASE INHIBITOR

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

HIV - 2 Integrase inhibitors

  Mutations associated with resistance Mutations associated with "possible resistance"
RAL
T66K [10]
E92Q [1, 2]
G118R [10]
F121Y [10]
G140A/S [7]
Y143A/C/G/H/R/S [1, 3, 4, 5, 8, 14]
Q148E/G/H/K/R [1, 2]
V151L [9]
N155H/S/T [1, 2, 9]
E157Q [2]
 
EVG T66I/A/K [6]
E92Q [6]
F121Y [9]
E138K
G140C/S
Y143A/C/G/H/R/S [14]
P145S [9]
S147G
Q148H/R/K [6]
V151L [9]
N155H/S/T [6, 9]
E157Q [11]

DTG G118R [12,13]
V151L [9]
S153Y
T66K + L74M
E92Q + N155H
Q148H/K/R + at least 2 mutations among: L74I or E138A/K/T or G140A/C/S [15]
Q148R + N155H
R263K [16]
T66K [9]
S153F
Q148H/K/R + 1 mutation among: L74I or E138A/K/T or G140A/C/S [15]

RAL: raltegravir, EVG: elvitegravir, DTG: dolutegravir .

References